Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810659 | 0.94 | KCNH2 (0.41) | NOS2SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL19973201 | 0.92 | KCNH2 (0.44) | NOS2SMN1; SMN2HCAR3HCAR2MAPT | |
| SCHEMBL6293331 | 0.88 | — | — | |
| SCHEMBL4521656 | 0.79 | DAO (0.37) | SMN1; SMN2HCAR2LMNATLR7KCNH2 | |
| SCHEMBL1072255 | 0.79 | — | — | |
| SCHEMBL2631524 | 0.78 | CYP1A2 (0.44) | NOS2NPC1RAB9AHCAR3HCAR2 | |
| SCHEMBL27886426 | 0.78 | HCAR2 (0.40) | NOS2SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL2765959 | 0.78 | HCAR2 (0.56) | NOS2HCAR3HCAR2HRH3GABRP | |
| SCHEMBL17950341 | 0.77 | — | — | |
| SCHEMBL5689957 | 0.76 | HCAR2 (0.50) | NOS2HCAR3HCAR2HRH3GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | PFIZER INC. | 2007-11-22 | — | — | US | claimed |
| EP-1551809-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. | 2004-07-22 | — | — | US | claimed |
| WO-2004033434-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | claimed |
| US-10358445-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2019-07-23 | — | — | US | disclosed |
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | RESPIVERT LTD. (GB) | 2018-07-19 | — | — | US | disclosed |
| US-9701670-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| WO-2017069270-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | 大正製薬株式会社 | 2017-04-27 | — | — | WO | disclosed |
| CN-105377847-A | Kinase inhibitors | CHIESI FARM SPA | 2016-03-02 | — | — | CN | disclosed |
| CN-105308046-A | Kinase inhibitors | CHIESI FARMA SPA | 2016-02-03 | — | — | CN | disclosed |
| CN-105308044-A | Derivatives of [1, 2, 4]-triazolo-[4, 3-A]-pyridine as p38 MAP kinase inhibitors | CHIESI FARMA SPA | 2016-02-03 | — | — | CN | disclosed |
| CN-101084217-A | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER REC TECH LTD (GB) | 2007-12-05 | — | — | CN | disclosed |
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | PFIZER INC. | 2007-11-22 | — | — | US | disclosed |
| CN-101006087-A | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER (US) | 2007-07-25 | — | — | CN | disclosed |
| US-7238721-B2 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1551809-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | PFIZER INC. | 2004-07-22 | — | — | US | disclosed |
| CN-1495173-A | Alpha-amino-N-allylamidinonitrobenzene compound and its synthesis | 伊斯曼柯达公司 | 2004-05-12 | — | — | CN | disclosed |
| WO-2004033434-A1 | PYRAZOLE COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10358445-B2 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | NOS2 594/4885SMN1; SMN2 1893/4885NPC1 547/4885 |
| US-20040142997-A1 | Pyrazole compounds for treatment of neurodegenerative disorders | APP, PARK7, BACE1 | NOS2 1255/4885SMN1; SMN2 520/4885NPC1 304/4885 |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | NOS2 594/4885SMN1; SMN2 1893/4885NPC1 547/4885 |
| US-20070270474-A1 | drugs have beta-amyloid peptide production inhibitory activity, such as 2-(2-benzo[b]thiophen-4-yl-acetylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide, useful for treatment of Alzheimer's disease and Down's Syndrome | APP, BACE1, PSEN1 | NOS2 504/4885SMN1; SMN2 1395/4885NPC1 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.